Eye surface and cataract surgery: Focus on Biotechnologies

Article

What are the best options of protecting and hydrating the epithelium during surgical procedures. The importance of the mucin protective layer on the corneal surface and implications for thiomer technology. Safety improvements with advanced fluidic technology systems: the need for a good machine to guarantee a precise flow control. Latest update on in vivo measurement methods of the accommodation in humans. Consequences and impacts on the IOL conception and design.

What are the best options of protecting and hydrating the epithelium during surgical procedures. The importance of the mucin protective layer on the corneal surface and implications for thiomer technology. Safety improvements with advanced fluidic technology systems: the need for a good machine to guarantee a precise flow control. Latest update on in vivo measurement methods of the accommodation in humans. Consequences and impacts on the IOL conception and design.

At this year's ESCRS Croma's symposia addressed those issues and also announced what it regards as a revolutionary new treatment for dry eyes in the form of a new generation of eye drops using Thiomer technology.

According to Croma this new patented technology of polymers has intrinsic natural stabilizing capabilities of the tear film. These connect directly with the mucus layer of the eye and results, say the company, have shown long-lasting ocular residence time. The thiolated polymers are hydrophilic macromolecules that exhibit free thiol groups on the polymeric backbone.

A report on the Croma symposium will follow at a later date in an issue of OTEurope.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.